CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the publication of preclinical data on its stabilized immune modulatory RNA (SIMRA) compounds that act as agonists of Toll-Like Receptors (TLR) 7 and 8. In this publication, data were reported from preclinical studies in human cell-based assays and in vivo in non-human primates in which SIMRA compounds induced immune responses. In the reported data the agonistic activity for TLR 7 and 8 was dependent on the chemical composition of the SIMRA compounds. The paper entitled “Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8” is published in the Proceedings of National Academy of Sciences, U.S.A. (Vol. 104: 13750-13755, 2007). The authors of the paper are Tao Lan, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat, Yukui Li, Daqing Wang, FuGang Zhu, Jimmy X. Tang, Mallikarjuna R. Putta, YanPing Cong, Anthony F. Trombino, Tim Sullivan, and Sudhir Agrawal of Idera.
